glioblastoma multiforme

glioblastoma multiforme
Name	Glioblastoma multiforme
Caption	Histopathological image of glioblastoma, showing characteristic features.
Field	Oncology, Neurosurgery, Neuro-oncology
Symptoms	Headaches, seizures, personality changes, neurological deficits
Complications	Increased intracranial pressure, Herniation (medicine)
Onset	Usually in older adults
Duration	Chronic
Types	Primary, secondary
Causes	Unknown
Risks	Ionizing radiation, Neurofibromatosis type 1, Li-Fraumeni syndrome
Diagnosis	Medical imaging (MRI), Biopsy
Differential	Anaplastic astrocytoma, Primary central nervous system lymphoma, Metastasis
Prevention	None known
Treatment	Surgical resection, Radiation therapy, Temozolomide
Medication	Corticosteroids, Anticonvulsants
Prognosis	Poor; median survival ~15 months
Frequency	~3 per 100,000 per year
Deaths	Highly fatal

glioblastoma multiforme. It is the most common and aggressive primary malignant brain tumor in adults, classified as a Grade IV astrocytoma by the World Health Organization. The tumor arises from astrocytes, star-shaped glial cells within the central nervous system, and is characterized by rapid growth and diffuse infiltration into surrounding brain tissue. Despite multimodal treatment, its prognosis remains poor, representing a significant challenge in the field of neuro-oncology.

Overview

Glioblastoma multiforme represents approximately 15% of all intracranial neoplasms and 45-50% of all malignant gliomas. It can occur at any age but has a peak incidence in individuals between 45 and 75 years old. The tumor is most commonly located in the cerebral hemispheres, particularly the frontal and temporal lobes, but can arise anywhere within the central nervous system. Historically, its classification and understanding have evolved through the work of organizations like the World Health Organization and researchers such as Harvey Cushing.

Causes and risk factors

The exact etiology of glioblastoma multiforme is unknown in most cases. The only well-established environmental risk factor is exposure to moderate-to-high doses of ionizing radiation, such as that used in previous treatments for tinea capitis or acute lymphoblastic leukemia. Certain rare genetic syndromes predispose individuals to glioma development, including neurofibromatosis type 1, Li-Fraumeni syndrome, and Turcot syndrome. Studies, including some by the International Agency for Research on Cancer, have found no conclusive link to common environmental factors like mobile phone use or dietary nitrosamines.

Pathophysiology

Glioblastoma multiforme is characterized by severe genetic instability and heterogeneity. Key molecular alterations include mutations in the IDH1 gene, which are typically absent in primary glioblastoma, and amplification or mutation of the EGFR gene. The tumor exhibits hallmark features such as necrosis surrounded by pseudopalisading cells and prominent microvascular proliferation. These pathological features are driven by dysregulated signaling pathways, including the PI3K/AKT/mTOR pathway and the RAS/MAPK pathway.

Diagnosis

Diagnosis typically begins with neurological examination followed by advanced medical imaging. Magnetic resonance imaging is the modality of choice, often showing a ring-enhancing lesion with surrounding vasogenic edema on T1-weighted sequences with gadolinium contrast. Definitive diagnosis requires histopathological examination of tissue obtained via stereotactic biopsy or craniotomy by a neuropathologist. The diagnostic criteria are standardized by the World Health Organization and often involve testing for molecular markers like MGMT promoter methylation status.

Treatment

The standard first-line treatment, established by the landmark Stupp protocol, involves maximal safe surgical resection followed by concurrent radiation therapy and the alkylating chemotherapy agent temozolomide, then adjuvant temozolomide. Corticosteroids like dexamethasone are used to manage cerebral edema, and anticonvulsants may be prescribed for seizure control. For recurrent disease, options include a second surgery, bevacizumab (an anti-VEGF antibody), tumor treating fields (Optune), or enrollment in clinical trials at institutions like the National Cancer Institute.

Prognosis

The prognosis for glioblastoma multiforme remains dismal, with a median survival of approximately 15 months with standard treatment and less than 10% of patients surviving five years. Prognostic factors include patient age, Karnofsky Performance Status, extent of surgical resection, and molecular markers. Methylation of the MGMT gene promoter is associated with better response to temozolomide and improved survival. Despite aggressive therapy, recurrence is nearly universal, often within 2-3 cm of the original tumor margin, leading to progressive neurological decline.

Research directions

Current research is focused on understanding tumor heterogeneity and developing targeted therapies. Major areas of investigation include immunotherapy approaches such as checkpoint inhibitors (e.g., pembrolizumab), chimeric antigen receptor T-cell therapy, and oncolytic viruses like DNX-2401. Other promising directions involve disrupting tumor metabolism, using advanced drug delivery systems to cross the blood-brain barrier, and applying artificial intelligence to MRI analysis for better prognostication. Large collaborative efforts like The Cancer Genome Atlas have been instrumental in mapping the genomic landscape of the disease.

Category:Central nervous system tumors Category:Neuro-oncology Category:Death